DUBLIN–(BUSINESS WIRE)–Research and Markets has actually announced the addition of the “Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2016” report to their offering.
This report offers comprehensive guide when it come to the therapeutic progress for Chronic Lymphocytic Leukemia (CLL), finish along with comparative analysis at numerous stages, therapeutics assessment by drug target, mechanism of action (MoA), path of administration (RoA) and molecule type, along along with latest updates, and featured news and press releases. It likewise reviews essential gamers associated with the therapeutic progress for Chronic Lymphocytic Leukemia (CLL) and distinct features when it come to late-phase and discontinued projects.
The report increases decision making capabilities and assistance to produce efficient contrarily strategies to get competitive advantage. It strengthens R&D pipelines by recognizing brand-new targets and MOAs to make first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Chronic Lymphocytic Leukemia (CLL) Overview
- Therapeutics Development
- Pipeline product and services for Chronic Lymphocytic Leukemia (CLL) – Overview
- Pipeline product and services for Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis
- Chronic Lymphocytic Leukemia (CLL) – Therapeutics under progress by Companies
- Chronic Lymphocytic Leukemia (CLL) – Therapeutics under Investigation by Universities/Institutes
- Chronic Lymphocytic Leukemia (CLL) product and services Glance
- Late phase Products
- Clinical phase Products
- Early phase Products
- Chronic Lymphocytic Leukemia (CLL) – product and services under progress by Companies
- Chronic Lymphocytic Leukemia (CLL) – product and services under Investigation by Universities/Institutes
- Chronic Lymphocytic Leukemia (CLL) – Organizations associated with Therapeutics Development
- 4SC AG
- AbbVie Inc.
- Acetylon Pharmaceuticals, Inc.
- Altor BioScience Corporation
- Amgen Inc.
- Arno Therapeutics, Inc.
- Astellas Pharma Inc.
- Astex Pharmaceuticals, Inc.
- AstraZeneca Plc
- Baliopharm AG
- Bayer AG
- BeiGene, Ltd.
- Bellicum Pharmaceuticals, Inc.
- Biogen, Inc.
- BioInvent Worldwide AB
- Bionovis SA
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Celgene Corporation
- Cellectis S.A.
- Celltrion, Inc.
- Cellular Biomedicine Group, Inc.
- Clonz Biotech Personal Limited
- Coherus BioSciences, Inc.
- Cyclacel Pharmaceuticals, Inc.
- Eli Lilly and Company
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche Ltd.
- GeneaMed Ltd.
- Genentech, Inc.
- Genor BioPharma Co., Ltd.
- Gilead Sciences, Inc.
- Grupo Ferrer Internacional, S.A.
For much more guide head to http://ift.tt/29x60uz
